research use only
Cat.No.S7576
| Related Targets | EGFR VEGFR PDGFR FGFR c-Met Src MEK CSF-1R FLT3 HER2 |
|---|---|
| Other Axl Inhibitors | Bemcentinib (R428) Dubermatinib(TP-0903) LDC1267 CEP-40783 (RXDX-106) SGI-7079 Tamnorzatinib (ONO-7475) RU-301 PF-07265807 |
| Cell Lines | Assay Type | Concentration | Incubation Time | Formulation | Activity Description | PMID |
|---|---|---|---|---|---|---|
| 32D cells | Function assay | 1 h | Inhibition of EGFR extracellular/transmembrane domain-tagged Mer intracellular domain (unknown origin) expressed in 32D cells assessed as inhibition EGF-stimulated of phosphorylation pretreated for 1 hr prior to EGF stimulation by Western blot analysis, IC50=2.7 nM | |||
| 697 cells | Function assay | 1 h | Inhibition of Mer phosphorylation in human 697 cells preincubated for 1 hr by densitometry, IC50=2.7 nM | |||
| Molm-14 cells | Function assay | 1 h | Inhibition of Flt3 phosphorylation in human Molm-14 cells preincubated for 1 hr by densitometry, IC50=0.014 μM | |||
| A549 cells | Function assay | 50-300 nM | Inhibition of Mer-mediated colony formation in human A549 cells at 50 to 300 nM measured after 2 weeks by soft agar colony formation assay | |||
| Click to View More Cell Line Experimental Data | ||||||
|
In vitro |
DMSO
: 100 mg/mL
(194.88 mM)
Ethanol : 60 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 513.12 | Formula | C28H41ClN6O |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 2070015-17-5 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | UNC2025 hydrochloride | Smiles | CCCCNC1=NC=C2C(=CN(C2=N1)C3CCC(CC3)O)C4=CC=C(C=C4)CN5CCN(CC5)C.Cl | ||
| Targets/IC50/Ki |
Mer
(Cell-free assay) 0.74 nM
FLT3
(Cell-free assay) 0.8 nM
Axl
(Cell-free assay) 14 nM
Tyro3
(Cell-free assay) 17 nM
|
|---|---|
| In vitro |
In 697 B-ALL cells, UNC-2025 potently inhibits Mer phosphorylation with IC50 of 2.7 nM. In A549 NSCLC and Molm-14 AML cell lines, UNC-2025 causes significant inhibition of colony formation dependent on Mer8 and Flt3. In H2228 and H1299 cell lines, UNC-2025 inhibits MERTK oncogenic signaling downstream, such as basal and stimulated pAKT and pERK1/2. In four NSCLC cell lines, UNC-2025 also induces apoptotic cell death, and decreases colony formation.
|
| In vivo |
In mice bearing 697 acute leukemia tumors, UNC-2025 (3 mg/kg, p.o.) shows good solubility and DMPK properties, and results in effective target inhibition. In mice bearing H2228 or A549 tumors, UNC-2025 (50 mg/kg, p.o.) inhibits tumor growth.
|
References |
|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.